Roche Backs Blueprint's Precision Therapy Pralsetinib To Challenge Lilly
Paying $675m Upfront For Rights To RET Inhibitor
The collaboration between the Swiss major and Blueprint Medicines, which could be worth up to $1.7bn, should help pralsetinib provide stiff competition to Eli Lilly's RET mutation drug Retevmo.
